Mabwell (Shanghai) Bioscience Co., Ltd.
688062.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.9B
Close$
Share Statistics
| Market cap | $9.90 Billion |
|---|---|
| Enterprise Value | $10.87 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 0.52 |
| Outstanding Shares | 428,610,414 |
Return
| Return on Equity | -107.68% |
|---|---|
| Return on Assets | -17.76% |
| Return on Invested Capital | -29.80% |
Valuation & Multiples
| P/E Ratio | -10.73 |
|---|---|
| PEG | -138.04 |
| Price to Sales | 11.47 |
| Price to Book Ratio | 11.47 |
| Enterprise Value to Revenue | 12.44 |
| Enterprise Value to EBIT | -12.2 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 3.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$185.04 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$214.87 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Mabwell (Shanghai) Bioscience Co., Ltd.
1,356 employees
CEO: Datao Liu Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company...